Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Johnson and Johnson
Accenture
Harvard Business School
US Department of Justice
Cerilliant
Chubb
Healthtrust

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NALTREXONE

« Back to Dashboard

Clinical Trials for Naltrexone

Trial ID Title Status Sponsor Phase Summary
NCT00000195 Neurobiology of Opioid Dependence: 4 - 4 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.
NCT00000195 Neurobiology of Opioid Dependence: 4 - 4 Withdrawn Yale University Phase 2 The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.
NCT00000196 Neurobiology of Opioid Dependence: 5 - 5 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.
NCT00000196 Neurobiology of Opioid Dependence: 5 - 5 Withdrawn Yale University Phase 2 The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.
NCT00000230 Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.
NCT00000230 Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 Completed University of Vermont Phase 2 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.
NCT00000231 Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13 Completed University of Vermont Phase 2 The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Naltrexone

Condition Name

Condition Name for Naltrexone
Intervention Trials
Alcoholism 53
Alcohol Dependence 48
Obesity 20
Opioid-Related Disorders 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Naltrexone
Intervention Trials
Alcoholism 99
Opioid-Related Disorders 45
Disease 34
Alcohol Drinking 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Naltrexone

Trials by Country

Trials by Country for Naltrexone
Location Trials
United States 658
China 12
Germany 12
Canada 10
Russian Federation 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Naltrexone
Location Trials
New York 58
Connecticut 47
Pennsylvania 41
California 41
Texas 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Naltrexone

Clinical Trial Phase

Clinical Trial Phase for Naltrexone
Clinical Trial Phase Trials
Phase 4 76
Phase 3 58
Phase 2/Phase 3 23
[disabled in preview] 159
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Naltrexone
Clinical Trial Phase Trials
Completed 225
Recruiting 53
Not yet recruiting 18
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Naltrexone

Sponsor Name

Sponsor Name for Naltrexone
Sponsor Trials
National Institute on Drug Abuse (NIDA) 77
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 53
Yale University 33
[disabled in preview] 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Naltrexone
Sponsor Trials
Other 333
NIH 144
Industry 94
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Argus Health
Accenture
Mallinckrodt
Johnson and Johnson
Julphar
Medtronic
QuintilesIMS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.